Rural clinics face severe staffing limits and high referral drop-offs for annual diabetic eye exams. By embedding AEYE-DS,the only FDA-cleared autonomous AI screening available on portable handheld and tabletop devices,clinics can perform a 1-minute point-of-care test directly during routine visits. This streamlines clinical workflows, triples screening compliance, satisfies HEDIS/MIPS measures, and leverages RHTP funding alongside CPT 92229 reimbursement to protect operating margins while preve

New published clinical data confirms AEYE-DS as the only FDA-cleared autonomous AI solution for both portable handheld and tabletop imaging. With >99% imageability and 100% sensitivity for severe diabetic retinopathy, AEYE-DS enables effortless 1-minute point-of-care screening.

A meta-analysis in npj Digital Medicine shows point-of-care AI screening triples diabetic eye referral completion in US clinics. Discover how AEYE-DS simplifies workflows and boosts patient compliance.